Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbbVie

172.65
+2.491.46%
Volume:2.79M
Turnover:482.22M
Market Cap:305.41B
PE:72.24
High:174.66
Open:171.08
Low:170.91
Close:170.16
Loading ...

Drugmakers Down Premarket After Trump Threatens Tariffs on Sector

THOMSON REUTERS
·
09 Apr

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

Dow Jones
·
09 Apr

AbbVie Hold Rating: Balancing Strong Immunology Growth with Challenges in Aesthetics, Neuroscience, and Oncology

TIPRANKS
·
09 Apr

AbbVie Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
09 Apr

Biopharma Shakeup: Goldman Boosts J&J, Eli Lilly While Flagging Risks at Pfizer and AbbVie

GuruFocus
·
09 Apr

AbbVie Coverage Assumed by Goldman Sachs at Neutral

Dow Jones
·
09 Apr

AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis

Zacks
·
08 Apr

Goldman turns cautious on major pharma names, sees select upside at Eli Lilly

Investing.com
·
08 Apr

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

Zacks
·
08 Apr

AbbVie Gets Expanded Europe OK for Rinvoq in Giant Cell Arteritis

Dow Jones
·
08 Apr

AbbVie assumed with a Neutral at Goldman Sachs

TIPRANKS
·
08 Apr

AbbVie Secures European Marketing Clearance for Giant Cell Arteritis Treatment Rinvoq

MT Newswires Live
·
08 Apr

BRIEF-Abbvie Announces European Commission Approval Of Rinvoq For Adults

Reuters
·
08 Apr

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis

PR Newswire
·
08 Apr

AbbVie (NYSE:ABBV) Showcases Cancer Treatment Advancements at AACR Annual Meeting

Simply Wall St.
·
08 Apr

Tariffs Pose $46 Billion Risk to Pharmaceutical Industry -- Analysis

Dow Jones
·
05 Apr

Shares of Some U.S. Drugmakers Down After Trump Says Pharmaceutical Sector Is 'Under Review' for Tariffs

THOMSON REUTERS
·
04 Apr

BUZZ-US drugmakers fall after Trump's new tariff warnings

Reuters
·
04 Apr

AbbVie (ABBV) Stock Moves -1.73%: What You Should Know

Zacks
·
04 Apr

AbbVie Issues Q1 Adjusted Earnings Outlook, Cuts Full-Year Guidance

MT Newswires Live
·
04 Apr